Literature DB >> 19883173

Vestibular neuritis: recurrence and incidence of secondary benign paroxysmal positional vertigo.

Marco Mandalà1, Giovanni Paolo Santoro, Julianne Awrey, Daniele Nuti.   

Abstract

CONCLUSIONS: Recurrence of vestibular neuritis (VN) is a rare event in long-term follow-up. The incidence of benign paroxysmal positional vertigo (BPPV) in VN patients represents a quite common outcome. To our knowledge, this study represents the only long-term longitudinal study on recurrence of VN and incidence of secondary BPPV in VN.
OBJECTIVES: To study a large number of VN patients longitudinally to identify the recurrence rate of VN and incidence of BPPV, other peripheral vestibular disorders, sudden hearing loss or Bell's palsy.
METHODS: This prospective cohort study assessed a VN patient-based clinic population. All patients received a complete bedside clinical examination and caloric irrigation.
RESULTS: Long-term (range 4-6 years, mean 4.9 years) longitudinal follow-up examination of 51 VN patients demonstrated a low recurrence rate (1/51 patients, 2.0%). With recurrence, VN affected the same ear after 6 months and caused less severe symptoms. BPPV appears to be more frequent (5/51 patients, 9.8%) in VN patients than in the general population, consistently affecting the posterior canal of the same ear. BPPV occurrence after VN predominantly affects VN patients who did not fully recover from the disease. Moreover, BPPV after VN appears to be more difficult to treat than idiopathic BPPV.

Entities:  

Mesh:

Year:  2010        PMID: 19883173     DOI: 10.3109/00016480903311278

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  19 in total

1.  Acute vestibulopathy.

Authors:  Yoon-Hee Cha
Journal:  Neurohospitalist       Date:  2011-01

2.  Benign paroxysmal positional vertigo secondary to vestibular neuritis.

Authors:  Dimitrios G Balatsouras; George Koukoutsis; Panayotis Ganelis; Nicolas C Economou; Antonis Moukos; Andreas Aspris; Michael Katotomichelakis
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-04-11       Impact factor: 2.503

Review 3.  The Price of Immune Responses and the Role of Vitamin D in the Inner Ear.

Authors:  Béla Büki; Heinz Jünger; Yan Zhang; Yunxia Wang Lundberg
Journal:  Otol Neurotol       Date:  2019-07       Impact factor: 2.311

4.  Residual dizziness after successful repositioning maneuvers for idiopathic benign paroxysmal positional vertigo in the elderly.

Authors:  Roberto Teggi; Leone Giordano; Stefano Bondi; Beatrice Fabiano; Mario Bussi
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-11-11       Impact factor: 2.503

5.  Video Head Impulse Test Findings in Patients With Benign Paroxysmal Positional Vertigo Secondary to Idiopathic Sudden Sensorineural Hearing Loss.

Authors:  Yingzhao Liu; Yangming Leng; Renhong Zhou; Jingjing Liu; Hongchang Wang; Kaijun Xia; Bo Liu; Hongjun Xiao
Journal:  Front Neurol       Date:  2022-06-02       Impact factor: 4.086

6.  Optimizing Testing for BPPV - The Loaded Dix-Hallpike.

Authors:  Luke Andera; William James Azeredo; Joseph Scott Greene; Haiyan Sun; Jeffrey Walter
Journal:  J Int Adv Otol       Date:  2020-08       Impact factor: 1.017

7.  The spectrum of acute vestibular neuropathy through modern vestibular testing: A descriptive analysis.

Authors:  Dario Andrés Yacovino; Estefanía Zanotti; Marcello Cherchi
Journal:  Clin Neurophysiol Pract       Date:  2021-04-14

8.  Clinical evaluation of posterior canal benign paroxysmal positional vertigo.

Authors:  Titus S Ibekwe; C Rogers
Journal:  Niger Med J       Date:  2012-04

9.  Inner ear disease and benign paroxysmal positional vertigo: a critical review of incidence, clinical characteristics, and management.

Authors:  M Riga; A Bibas; J Xenellis; S Korres
Journal:  Int J Otolaryngol       Date:  2011-08-02

10.  Gender-based comorbidity in benign paroxysmal positional vertigo.

Authors:  Oluwaseye Ayoola Ogun; Kristen L Janky; Edward S Cohn; Bela Büki; Yunxia Wang Lundberg
Journal:  PLoS One       Date:  2014-09-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.